Peter Attia Resigns from David Protein Amid Epstein Document Release
Dr. Peter Attia, a prominent figure in the field of longevity and preventive health, has recently stepped down from his position as Chief Science Officer at David Protein, a company renowned for its high-protein nutrition bars. This development follows the public release of over 1,700 documents, including email correspondences, associated with convicted sex offender Jeffrey Epstein. Attia’s name appeared in these documents, prompting scrutiny and subsequent actions.
Background on Peter Attia
Peter Attia is a Canadian-American physician who has gained significant recognition for his work in longevity science. He authored the bestselling book Outlive: The Science and Art of Longevity and hosts a popular podcast where he discusses strategies for optimizing health and extending lifespan. His insights have made him a sought-after expert in the field, leading to his recent appointment as a contributor to CBS.
David Protein’s Rise and Attia’s Involvement
Founded three years ago in New York, David Protein has made a notable impact in the nutrition industry. The company secured a $75 million Series A funding round in May of the previous year, led by Greenoaks with participation from Valor Equity Partners. Their flagship product, launched in September 2024, is a protein bar boasting 28 grams of protein, zero sugar, and only 150 calories. Attia played a pivotal role in the company’s development, serving on the executive team and contributing as an early investor.
The Epstein Connection and Attia’s Response
The recent document release linked Attia to Epstein through various email correspondences. In a detailed post on X (formerly Twitter), Attia expressed remorse over the content of some emails, describing them as crude. He emphasized that he was not involved in any criminal activities, had never visited Epstein’s private island, nor traveled on his plane. Attia elaborated on his acquaintance with Epstein, explaining the circumstances of their association and his reasons for maintaining contact even after Epstein’s 2008 conviction.
Impact on Biograph
The repercussions of this association have extended beyond David Protein. Biograph, a healthcare testing and longevity startup co-founded by Attia and entrepreneur John Hering, appears to be distancing itself from him. The company has declined to comment on Attia’s current involvement. Notably, references to Attia on Biograph’s website have been removed or now lead to error messages.
Biograph emerged from stealth mode a year ago, offering premium preventive health services to subscribers at annual fees ranging from $7,500 to $15,000. The startup has attracted investments from firms like Vy Capital, Human Capital, Alpha Wave, and WndrCo, as well as angel investors including Balaji Srinivasan. Attia was previously highlighted as a co-founder in the company’s press releases and website.
Broader Implications
The unfolding events underscore the complexities and potential repercussions of professional associations, especially when linked to controversial figures. Attia’s resignation from David Protein and the apparent distancing by Biograph reflect the challenges organizations face in managing reputational risks. As the longevity and health optimization sectors continue to grow, the integrity and backgrounds of their leading figures remain under close scrutiny.
